Goldman Sachs Group Inc Next Cure, Inc. Transaction History

Goldman Sachs Group Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 14, 2024	SELL	$1.46 - $1.83 $315,748 - $395,766	-216,266 Reduced 69.82%	93,478 $138,000
Q1 2023 May 11, 2023	SELL	$1.46 - $1.83 $315,748 - $395,766	-216,266 Reduced 69.82%	93,478 $138,000
Q4 2022 May 14, 2024	SELL	$1.2 - $3.07 $31,912 - $81,643	-26,594 Reduced 7.91%	309,744 $436,000
Q4 2022 Feb 13, 2023	SELL	$1.2 - $3.07 $31,912 - $81,643	-26,594 Reduced 7.91%	309,744 $436,000
Q3 2022 May 14, 2024	SELL	$2.72 - $5.19 $7,262 - $13,857	-2,670 Reduced 0.79%	336,338 $925,000
Q3 2022 Nov 10, 2022	SELL	$2.72 - $5.19 $7,262 - $13,857	-2,670 Reduced 0.79%	336,338 $0
Q2 2022 May 14, 2024	BUY	$3.38 - $5.27 $1.15 Million - $1.79 Million	339,008 New	339,008 $1.59 Million
Q2 2022 Aug 15, 2022	SELL	$3.38 - $5.27 $115,183 - $179,591	-34,078 Reduced 9.13%	339,008 $1.59 Million
Q1 2022 May 16, 2022	BUY	$4.76 - $6.24 $190,200 - $249,337	39,958 Added 11.99%	373,086 $1.81 Million
Q4 2021 Feb 14, 2022	BUY	$5.7 - $9.1 $1.33 Million - $2.12 Million	233,266 Added 233.59%	333,128 $2 Million
Q3 2021 Nov 10, 2021	BUY	$6.74 - $8.02 $673,069 - $800,893	99,862 New	99,862 $673,000

15.9M

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $36.4M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.